CTLA4 and neoplasm: Locally, delivery of IL12 to the tumor microenvironment promotes tumor regression in the B16 melanoma model [74], in the EL4 thymoma model [75], and in mouse models of glioblastoma in combination with CTLA4 blockade [76].